As Medicines Co (MDCO) Market Valuation Declined, Bridger Management LLC Increased by $12.87 Million Its Stake

March 15, 2018 - By Darrin Black

Investors sentiment decreased to 0.78 in 2017 Q3. Its down 0.44, from 1.22 in 2017Q2. It worsened, as 32 investors sold MDCO shares while 64 reduced holdings. 19 funds opened positions while 56 raised stakes. 85.15 million shares or 1.36% less from 86.33 million shares in 2017Q2 were reported. Pointstate Ltd Partnership holds 1.68M shares. Vanguard Gp owns 0.01% invested in The Medicines Company (NASDAQ:MDCO) for 6.09 million shares. Teachers Retirement Of The State Of Kentucky accumulated 0.07% or 160,955 shares. Tower Limited Liability Com (Trc) holds 10,106 shares or 0.03% of its portfolio. Parametric Port Associates Limited Co owns 136,828 shares. Us Bancshares De invested in 0% or 3,233 shares. Hightower Advsr Limited Company has 7,187 shares. Teacher Retirement Sys Of Texas reported 5,940 shares. Partner Fund Lp invested in 1.50 million shares or 1.09% of the stock. Germany-based Dekabank Deutsche Girozentrale has invested 0.01% in The Medicines Company (NASDAQ:MDCO). Legal General Grp Public Ltd has invested 0% of its portfolio in The Medicines Company (NASDAQ:MDCO). Louisiana State Employees Retirement System holds 0.05% or 25,900 shares in its portfolio. Alphaone Investment Service Ltd Liability has invested 0.01% of its portfolio in The Medicines Company (NASDAQ:MDCO). Hall Laurie J Trustee has invested 0.02% in The Medicines Company (NASDAQ:MDCO). State Of Wisconsin Investment Board invested in 52,000 shares or 0.01% of the stock.

Since December 7, 2017, it had 1 buy, and 1 sale for $1.60 million activity. MEANWELL CLIVE sold $3.71M worth of The Medicines Company (NASDAQ:MDCO) on Friday, December 15.

Roberto Mignone increased its stake in Medicines Co (MDCO) by 14.13% based on its latest 2017Q3 regulatory filing with the SEC. Bridger Management Llc bought 347,714 shares as the company’s stock declined 20.30% while stock markets rallied. The hedge fund run by Roberto Mignone held 2.81 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $104.04 million, up from 2.46 million at the end of the previous reported quarter. Bridger Management Llc who had been investing in Medicines Co for a number of months, seems to be bullish on the $2.52 billion market cap company. The stock decreased 0.98% or $0.34 during the last trading session, reaching $34.43. About 708,495 shares traded. The Medicines Company (NASDAQ:MDCO) has risen 16.70% since March 15, 2017 and is uptrending. It has by 0.00% the S&P500.

Bridger Management Llc, which manages about $3.11B and $1.67 billion US Long portfolio, decreased its stake in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) by 375,194 shares to 383,933 shares, valued at $45.11 million in 2017Q3, according to the filing. It also reduced its holding in Envision Healthcare Corp by 242,285 shares in the quarter, leaving it with 1.09M shares, and cut its stake in Charter Communications Inc N.

More notable recent The Medicines Company (NASDAQ:MDCO) news were published by: which released: “The Medicines Company to Participate in the Cowen 38” on March 08, 2018, also with their article: “The Medicines Company Reaches Enrollment Target for ORION-10 Ahead of Schedule” published on March 08, 2018, published: “In Cholesterol Drug Battle, Sanofi/Regeneron Jolt Prospects Of The Medicines …” on March 12, 2018. More interesting news about The Medicines Company (NASDAQ:MDCO) were released by: and their article: “The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule” published on February 20, 2018 as well as‘s news article titled: “The Medicines Company: The Upcoming ODYSSEY Trial Results Could Make It A More …” with publication date: March 08, 2018.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Among 11 analysts covering The Medicines Co (NASDAQ:MDCO), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. The Medicines Co has $85.0 highest and $40.0 lowest target. $53.55’s average target is 55.53% above currents $34.43 stock price. The Medicines Co had 36 analyst reports since August 28, 2015 according to SRatingsIntel. Oppenheimer upgraded The Medicines Company (NASDAQ:MDCO) rating on Wednesday, November 29. Oppenheimer has “Buy” rating and $50.0 target. The rating was upgraded by Citigroup on Monday, January 22 to “Buy”. The firm has “Buy” rating by Cowen & Co given on Tuesday, October 10. The stock of The Medicines Company (NASDAQ:MDCO) has “Hold” rating given on Thursday, February 22 by Oppenheimer. As per Wednesday, November 4, the company rating was initiated by Chardan Capital Markets. The firm earned “Outperform” rating on Wednesday, November 16 by RBC Capital Markets. The company was maintained on Monday, March 21 by Chardan Capital Markets. The firm earned “Hold” rating on Wednesday, July 12 by Oppenheimer. Jefferies maintained the stock with “Buy” rating in Monday, June 26 report. The firm has “Outperform” rating given on Monday, November 16 by RBC Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.